



Outset Medical Appoints New Chief Financial Officer

June 6, 2019

Former Illumina Executive Rebecca Chambers Joins Outset as Company Scales to Meet Demand

SAN JOSE, Calif.–(BUSINESS WIRE)—Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced the appointment of Rebecca Chambers as Chief Financial Officer. Chambers joins Outset from Illumina, the leader in DNA sequencing technology.

Over the course of her career at Illumina, Chambers led numerous financial functions including treasury, clinical financial planning and analysis and investor relations (IR). Prior to Illumina, she led IR and corporate communications at Myriad Genetics, a molecular diagnostics company in Salt Lake City, Utah, as well as various roles at Life Technologies, now part of Thermo Fisher Scientific, Bank of America Merrill Lynch, and Millennium Pharmaceuticals, now Takeda Pharmaceuticals.

"Rebecca's deep capital markets expertise and growth-company track record is ideally suited to our stage of commercial expansion," said Leslie Trigg, Outset's Chief Executive Officer. "We recognized in Rebecca a best-in-class ability to build a strong financial foundation and effective, transparent relationships with the investment community. We are thrilled to welcome her to the leadership team."

"I am honored to be a part of Outset at this time in its growth trajectory. It is a rare opportunity to join a team passionate about transforming a stagnant, but rapidly growing market with a huge unmet patient need," said Chambers. "The Tablo® Hemodialysis System has the potential to fundamentally change the way dialysis is delivered and improve the lives of patients and providers, while also driving significant cost efficiencies."

Although more than 91 million dialysis treatments take place in the United States each year at an estimated annual cost of \$65 billion, little meaningful technology or service model innovation has been introduced in decades. Tablo was specifically designed to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen aim to make Tablo easy to learn and use for healthcare professionals and patients alike.

Media Contact

Kevin Knight
206.451.4823
media@outsetmedical.com

About the Tablo Hemodialysis System

Tablo is an FDA-cleared enterprise solution for dialysis, designed specifically to reduce the cost and complexity of dialysis across all care settings. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from the burdensome infrastructure required to operate conventional dialysis machines. The machine's integrated functionality enables it to serve as a dialysis clinic on wheels and enables providers to standardize to a single platform that can be used across a wide spectrum of care settings. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use. Leading health systems and medical centers across the U.S. have adopted Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters.

About Outset Medical

Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset's Tablo System is FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company has concluded a clinical trial to expand Tablo's labeled indication to include home use. For more information visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.